Clinical Trials
54 trialsPomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
National Institutes of Health Clinical Center (CC)
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
University of Michigan Rogel Cancer Center
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
National Cancer Institute (NCI)
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics, Inc.
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
Dana-Farber Cancer Institute
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
VEGAS
Baylor College of Medicine
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
M.D. Anderson Cancer Center
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta, Inc.
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Washington University School of Medicine
Bevacizumab/Doxorubicin/Radiation for Sarcoma
Massachusetts General Hospital
Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
OHSU Knight Cancer Institute
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
Iovance Biotherapeutics, Inc.
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
FLAGSHP-1
Erasca, Inc.
CLOVER-2
Cellectar Biosciences, Inc.
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Jonsson Comprehensive Cancer Center
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
Eisai Inc.
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
Sonnet BioTherapeutics
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
HEROS
Baylor College of Medicine
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Institutes of Health Clinical Center (CC)
POTENTIATE
Boundless Bio, Inc.
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
Taiho Pharmaceutical Co., Ltd.
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
REGO-INTER-EWI
Gustave Roussy, Cancer Campus, Grand Paris
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
Seattle Children's Hospital
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
University of Iowa
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
M032-HSV-1
University of Alabama at Birmingham
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
University of Nebraska
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
University of Alabama at Birmingham
MEDISARC-SBRT
Institut Claudius Regaud
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
Baylor College of Medicine